The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 480.00
Bid: 480.00
Ask: 482.50
Change: 0.00 (0.00%)
Spread: 2.50 (0.521%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 480.00
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Treatt (TET): New facility to drive growth

11 Jul 2022 07:00

Edison Investment Research Limited Treatt (TET): New facility to drive growth 11-Jul-2022 / 07:00 GMT/BST


 

London, UK, 11 July 2022

 

Treatt (TET): New facility to drive growth

Treatt has performed consistently well over the last few years, as it has moved from a commodity trading house to a partner and provider of advanced ingredients solutions. Following its successful expansion of capacity in the United States, it relocated its UK headquarters and manufacturing capability, with almost all staff now working from the new site. This should mark an inflection point for the business as the new facility is significantly more automated, allowing for greater efficiencies. Treatt is exposed to high-growth categories that are in the sweet spot of consumer preferences, such as sugar reduction, and reported at H122 that its order book is up 25% on last year. We maintain our forecasts and note that, as flagged by management, H2 is expected to witness both higher revenue and higher margins than H1, thus reverting to a more normal H1/H2 seasonal split after two years distorted by the COVID-19 pandemic.

 

Treatt trades at 23.7x and 16.1x FY22 P/E and EV/EBITDA, representing discounts of c 10% and c 5% respectively to its peers. We note the current share price is discounting medium-term sales growth of 5.7%, falling to 2.0% in perpetuity, with a WACC of 7.7% and a terminal EBIT margin of 20.0%. We forecast net debt at end FY22, moving to a net cash position thereafter.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Sara Welford +44 (0)20 3077 5700 consumer@edisongroup.com

Russell Pointon +44 (0)20 3077 5700 consumer@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1393751 11-Jul-2022 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
30th Apr 20244:02 pmRNSVoting Rights and Capital
10th Apr 20247:00 amRNSHalf Year Trading Update & Notice of Results
19th Mar 20243:40 pmRNSNotification of Transactions of Directors
4th Mar 20247:00 amRNSAppointment of Chief Executive Officer
13th Feb 20249:35 amRNSHolding(s) in Company
31st Jan 20242:41 pmRNSNotification of Transaction of PDMR
25th Jan 20243:49 pmRNSResult of AGM
25th Jan 20247:00 amRNSAGM Trading Update
23rd Jan 20241:57 pmRNSTotal Voting Rights
21st Dec 20232:07 pmRNSNotification of Transaction of Director
15th Dec 20236:09 pmRNSNotification of Transactions - Replacement
15th Dec 20234:42 pmRNSNotification of Transactions of Directors
13th Dec 20237:00 amRNSInterim Chief Financial Officer Appointment
12th Dec 20234:24 pmRNSAnnual Report and Notice of Annual General Meeting
1st Dec 20237:01 amRNSBlock Listing Six Monthly Return
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
28th Nov 20234:15 pmRNS2023 Final Dividend
28th Nov 20237:00 amRNSFull Year Results
20th Oct 20237:00 amRNSCEO Succession
10th Oct 20237:00 amRNSTrading Update
18th Sep 20234:11 pmRNSHolding(s) in Company
15th Aug 20234:14 pmRNSNotification of Transactions of Directors
28th Jul 202310:43 amRNSTotal Voting Rights
13th Jul 202312:15 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202311:09 amRNSNotification of Transaction of Director
21st Jun 20234:05 pmRNSNotification of Transactions of Director
12th Jun 20234:13 pmRNSDirector Declaration
7th Jun 20232:28 pmRNSBlock Listing Application
1st Jun 20237:00 amRNSBlock listing Six Monthly Return
19th May 20235:10 pmRNSHolding(s) in Company
19th May 20234:28 pmRNSHolding(s) in Company
9th May 20237:00 amRNSHalf Year Results
12th Apr 20237:00 amRNSHalf Year Trading Update and Notice of Results
20th Mar 20233:28 pmRNSNotification of Transactions of Directors
7th Mar 20233:25 pmRNSDirector/PDMR Shareholding
22nd Feb 20233:06 pmRNSHolding(s) in Company
21st Feb 202312:51 pmRNSNotification of Transactions of Director
21st Feb 202312:49 pmRNSNotification of Transactions of Director
20th Feb 202311:01 amRNSNotification of Transaction of a Director
30th Jan 20231:49 pmRNSHolding(s) in Company
27th Jan 20233:10 pmRNSResult of AGM
27th Jan 20237:00 amRNSAGM Trading Update
10th Jan 20235:05 pmRNSVoting Rights and Capital
28th Dec 20227:00 amRNSNotification of Transaction of Director
28th Dec 20227:00 amRNSAnnual Report and Notice of Annual General Meeting
20th Dec 202212:20 pmRNSBoard Appointment and Board Committee Changes
16th Dec 20221:25 pmRNSNotification of Transactions of Directors
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Nov 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.